Statistics from Altmetric.com
There are a number of adjunctive pharmacotherapies available for individuals with peripheral arterial disease and intermittent claudication, in whom appropriate risk factor modification and antiplatelet treatment have been initiated. These include cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate, which have vasodilatation among their mechanisms of action and have been the subject of recent technology appraisal guidance offered by the National Institute for Health and Clinical Excellence (NICE).1 The guidance offered was based upon systematic review, meta-analysis and cost-effectiveness analysis and is summarised in box 1.
Summary of NICE guidelines1
For individuals with peripheral arterial disease and intermittent claudication, where vasodilator treatment is considered appropriate:
Naftidrofuryl oxalate is recommended as a treatment option, started with the least costly licenced preparation
Cilostazol, pentoxyfylline and inositol nicotinate are not recommended in this context
If cilostazol, pentoxyfylline and inositol nicotinate are currently …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.